OncoMatch/Clinical Trials/Leukemia — Acute Lymphoblastic (ALL)
Leukemia — Acute Lymphoblastic (ALL) Clinical Trials
OncoMatch filters Leukemia — Acute Lymphoblastic (ALL) trials by the molecular markers that determine eligibility — BCR, IKZF1, KMT2A, CD19, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Leukemia — Acute Lymphoblastic (ALL) trials
These are the molecular markers most commonly required or evaluated in Leukemia — Acute Lymphoblastic (ALL) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Leukemia — Acute Lymphoblastic (ALL) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Merck Sharp & Dohme LLC
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Daiichi Sankyo
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Children's Oncology Group
How OncoMatch finds Leukemia — Acute Lymphoblastic (ALL) trials for you
AI reads the protocol
Every Leukemia — Acute Lymphoblastic (ALL) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Leukemia — Acute Lymphoblastic (ALL) and mark your biomarker results — BCR, IKZF1, KMT2A — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.